Alison Tanchyk

Corporate leaders and Boards from all industries, including retail, life sciences, and manufacturing rely on Alison’s advice on anticorruption compliance issues including third–party due diligence, procedures, and training.

Most recently, she represented General Cable Corporation in connection with an FCPA investigation of its operations in Angola, Portugal, China, Egypt, and Thailand. The matter was resolved in December 2016 for a total of approximately $76 million in disgorgement and penalty via a non-prosecution agreement with the DOJ and administrative order with the SEC. Pursuant to the NPA, the DOJ imposed a penalty representing 50 percent off the bottom end of the Sentencing Guidelines range. Neither the DOJ nor the SEC required a compliance monitor. She also represented Olympus Corporation of the Americas in connection with an FCPA investigation of Olympus’s sales and marketing practices in Latin America resulting in a deferred prosecution agreement and $22.8 million fine, announced March 1, 2016.

Alison is the Co-Leader of the Florida Chapter of the Women’s White Collar Defense Association (WWCDA). She has repeatedly been named as one of Latin America’s top female lawyers by Latinvex .

Anti-Corruption

• Represented Olympus Corporation of the Americas in an FCPA investigation of their sales and marketing practices in Latin America. Resulted in a deferred prosecution agreement and $22.8 million fine.
• Representation of a Fortune 100 company in an FCPA internal investigation in Korea and China involving related inquiries by the U.S. Department of Justice and Securities and Exchange Commission.
• Representation of a Fortune 100 company in an FCPA internal anti-corruption and anti-competition investigation in Vietnam and Singapore and related inquiries by the World Bank.
• Representation of corporations in FCPA and foreign anti-corruption laws internal investigations in Russia, Asia, Africa, Eastern Europe, Central America, and South America.
• Counseling and training of public US companies, private U.S. companies and foreign companies regarding the development, implementation, evaluation, and auditing of anti-corruption compliance programs.

Healthcare Fraud and Abuse

• Cross-border healthcare fraud internal investigation involving allegations of fraudulent billing and bid-rigging.
• Representations of pharmaceutical manufacturers in connection with DOJ criminal and civil investigations involving allegations of, inter alia, off-label marketing.
• Representation of a pharmaceutical manufacturer in non-intervened Qui Tam litigation
• Representation of individuals in a DOJ investigation involving allegations of, inter alia, Anti-Kickback Statute, and health care fraud violations.
• Representation of a pharmaceutical manufacturer in internal investigation of its contracting protocols and procedures in its selection and use of a clinical study investigator.
• Representation of healthcare provider owners in connection with DOJ criminal and civil investigation of alleged conspiracy to commit healthcare fraud and money laundering.

Anti-trust

• Declination of prosecution of corporation in a federal criminal antitrust action involving, inter alia, allegations of price fixing and bid-rigging.
• Representation of a corporation in a federal civil antitrust action involving, inter alia, allegations of price fixing.

Tax

• Representation of an individual in a criminal tax fraud investigation involving allegations of use of an off-shore shell corporation and falsification of business deductions.
• Representation of a supermarket corporation and owners in a criminal tax fraud investigation involving allegations of unreported payroll.

Other

• Representation of a corporation and an individual in putative federal civil class actions involving, inter alia, RICO and 42 U.S.C. § 1983 claims.
• Representation of individuals in insider trading investigations.